Q2 EPS Estimate for Elanco Animal Health Lowered by Analyst

Elanco Animal Health Incorporated (NYSE:ELAN) – William Blair decreased their Q2 2025 earnings per share (EPS) estimates for Elanco Animal Health in a research note issued to investors on Tuesday, February 25th. William Blair analyst B. Vazquez now anticipates that the company will post earnings per share of $0.22 for the quarter, down from their prior forecast of $0.27. The consensus estimate for Elanco Animal Health’s current full-year earnings is $0.91 per share. William Blair also issued estimates for Elanco Animal Health’s Q3 2025 earnings at $0.13 EPS, Q4 2025 earnings at $0.14 EPS, FY2025 earnings at $0.80 EPS, Q1 2026 earnings at $0.29 EPS, Q2 2026 earnings at $0.28 EPS, Q3 2026 earnings at $0.16 EPS, Q4 2026 earnings at $0.18 EPS and FY2026 earnings at $0.91 EPS.

ELAN has been the topic of a number of other reports. Morgan Stanley decreased their price objective on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a research note on Wednesday. UBS Group decreased their price objective on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Wednesday. Leerink Partners began coverage on Elanco Animal Health in a research note on Monday, December 2nd. They set a “market perform” rating and a $14.00 price objective on the stock. Leerink Partnrs upgraded Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. Finally, Stifel Nicolaus decreased their target price on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday, February 21st. Four analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $15.83.

Elanco Animal Health Stock Performance

NYSE:ELAN opened at $11.19 on Thursday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. Elanco Animal Health has a 52-week low of $10.20 and a 52-week high of $18.80. The firm has a market cap of $5.53 billion, a price-to-earnings ratio of 27.96, a PEG ratio of 2.50 and a beta of 1.42. The business’s fifty day moving average is $11.71 and its 200 day moving average is $13.03.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.01 billion. During the same period in the prior year, the business earned $0.08 earnings per share. The business’s quarterly revenue was down 1.4% compared to the same quarter last year.

Hedge Funds Weigh In On Elanco Animal Health

Institutional investors have recently added to or reduced their stakes in the business. DDD Partners LLC bought a new position in Elanco Animal Health in the 4th quarter worth about $5,974,000. Geode Capital Management LLC boosted its holdings in shares of Elanco Animal Health by 0.8% in the 3rd quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company’s stock worth $115,623,000 after purchasing an additional 65,303 shares in the last quarter. Atom Investors LP boosted its holdings in shares of Elanco Animal Health by 310.3% in the 3rd quarter. Atom Investors LP now owns 345,855 shares of the company’s stock worth $5,081,000 after purchasing an additional 261,559 shares in the last quarter. Harbor Capital Advisors Inc. boosted its holdings in shares of Elanco Animal Health by 24.0% in the 4th quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company’s stock worth $13,135,000 after purchasing an additional 209,734 shares in the last quarter. Finally, Wellington Management Group LLP boosted its holdings in shares of Elanco Animal Health by 19.2% in the 3rd quarter. Wellington Management Group LLP now owns 4,007,805 shares of the company’s stock worth $58,875,000 after purchasing an additional 646,522 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.